The first perspective trial evaluating the efficacy of immunosuppressive therapy in LGL leukemia evidenced the relationship between the presence of Y640F STAT3 mutation and response to MTX [19]. Here, STAT3 is linked to T-cell large granular lymphocyte leukemia.